Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies

Foley, Peter; Freeman, Michael L.; Menter, Alan; Siller, Gregory; el-Azhary, Rokea A.; Gebauer, Kurt; Lowe, Nicholas J.; Jarratt, Michael; Murrell, Dédée F.; Rich, Phoebe; Pariser, David M.; Oseroff, Allan R.; Barnetson, Ross StC; Anderson, Christopher J.; Kossard, Steven; Gibson, Lawrence E.; Tope, Whitney D.

doi:10.1111/j.1365-4632.2008.04022.x

Cited by 75 publications

(82 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The histologic response rate was 73% in the treatment group. 87 In a similar study, 2 PDT illuminations were performed with ALA-PDT after debulking of nodular BCC, with a cumulative recurrence rate of 31% after 5 years and best response in small BCC less than 0.7 mm thick. 38 Other data with ALA-PDT are similar, with complete response rates of at least 60% to 70% and improved response when light irradiation was fractionated into 2 periods of illumination.…”

Section: Photodynamic Therapymentioning

confidence: 99%

See 1 more Smart Citation

Guidelines of care for the management of basal cell carcinoma

Baum¹,

Bordeaux²,

Brown³

et al. 2018

Journal of the American Academy of Dermatology

314

219

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually increasing annual incidence in the United States. When diagnosed early, the majority of BCCs are readily treated with office-based therapy, which is highly curative. In these evidence-based guidelines of care, we provide recommendations for the management of patients with BCC, as well as an in-depth review of the best available literature in support of these recommendations. We discuss biopsy techniques for a clinically suspicious lesion and offer recommendations for the histopathologic interpretation of BCC. In the absence of a formal staging system, the best available stratification based on risk for recurrence is reviewed. With regard to treatment, we provide recommendations on treatment modalities along a broad therapeutic spectrum, ranging from topical agents and superficially destructive modalities to surgical techniques and systemic therapy. Finally, we review the available literature and provide recommendations on prevention and the most appropriate follow-up for patients in whom BCC has been diagnosed. ( J Am Acad Dermatol

show abstract

Section: Photodynamic Therapymentioning

confidence: 99%

“…35,38,64,74,76,77,[80][81][82]86,87,99 Application of the photosensitizer is often preceded by light curettage of BCCs. 99 Usually a single treatment cycle is performed, but treatments may be repeated.…”

Section: Photodynamic Therapymentioning

confidence: 99%

Guidelines of care for the management of basal cell carcinoma

Baum¹,

Bordeaux²,

Brown³

et al. 2018

Journal of the American Academy of Dermatology

314

219

View full text Add to dashboard Cite

show abstract

“…Such reports, involving active comparators [23][24][25][26] and/or a placebo group, [27][28][29][30][31] exist in the AK literature, although patient populations may be small and blinding is often questionable. AK research is singularly well suited to intraindividual comparison studies-for example, split-face or split-scalp studies, in which different therapies are used to treat otherwise-identical areas of photodamaged skin.…”

Section: Overview Of the Clinical Literature On Aksmentioning

confidence: 99%

Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses

et al. 2015

View full text Add to dashboard Cite

Background Actinic keratosis (AK) and cheilitis (AC) are lesions that develop on photodamaged skin and may progress to form invasive squamous cell carcinomas (SCCs). Objective To provide guidance to Canadian health care practitioners regarding management of AKs and ACs. Methods Literature searches and development of graded recommendations were carried out as discussed in the accompanying introduction (chapter 1 of the NMSC guidelines). Results Treatment of AKs allows for secondary prevention of skin cancer in sun-damaged skin. Because it is impossible to predict whether a given AK will regress, persist, or progress, AKs should ideally be treated. This chapter discusses options for the management of AKs and ACs. Conclusions Treatment options include surgical removal, topical treatment, and photodynamic therapy. Combined modalities may be used in case of inadequate response. AKs are particularly common following the longterm immunosuppression in organ transplant patients, who should be monitored frequently to identify emerging lesions that require surgery.

show abstract

“…The importance and objective of treatment for AK and BCC are focused on their malignant transformation potential; intervention therefore must be geared towards eradication of the lesion and prevention of recurrence [2][3][4][5][6] . In AV and PA cases, the aim is the maximum reduction in number of lesions and to achieve an aesthetic improvement [7][8][9] .…”

Section: Original Articlesmentioning

confidence: 99%